Farxiga vs Lantus: Real-World Evidence Comparison

What Are Farxiga and Lantus and How Do They Differ?

Farxiga and Lantus address high blood sugar through completely different biology. Dapagliflozin blocks the SGLT2 transporter in the kidney's proximal tubule, forcing roughly 70 to 80 g of glucose into the urine each day. Insulin glargine replaces or supplements the body's own basal insulin, directly driving glucose into cells. The two drugs rarely compete head-to-head in the same patient because most guidelines position them at different stages of type 2 diabetes management.

Mechanism of Action

Dapagliflozin's glucosuria also lowers blood pressure by 3 to 4 mmHg systolic and generates mild osmotic diuresis, which accounts for part of its cardioprotective effect. Insulin glargine has a flat pharmacokinetic profile (no pronounced peak), which is why it is dosed once daily in most patients and carries lower meal-time hypoglycemia risk than NPH insulin.

Approved Indications

The FDA approved dapagliflozin for type 2 diabetes in 2014, added heart failure with reduced ejection fraction (HFrEF) in 2020, and expanded the indication to heart failure with preserved ejection fraction (HFpEF) in 2022. Insulin glargine has been FDA-approved for type 1 and type 2 diabetes since 2000 and remains one of the most prescribed insulins worldwide. Neither drug is approved for weight loss as a primary indication, though dapagliflozin consistently produces modest weight reduction in trials.

Glycemic Efficacy: How Well Does Each Drug Lower Blood Sugar?

Insulin glargine lowers HbA1c more reliably than dapagliflozin when baseline HbA1c is above 9%. Dapagliflozin's glucose-lowering is self-limiting: once the filtered glucose load drops, urinary excretion plateaus. Basal insulin titration has no such ceiling.

Randomized Trial Data

In a 24-week add-on trial (N=798) comparing dapagliflozin 10 mg to placebo in patients on background oral agents, dapagliflozin reduced HbA1c by 0.84% vs 0.30% for placebo (Ferrannini E et al., Diabetes Care 2010). Insulin glargine in the ORIGIN trial (N=12,537) reduced HbA1c from 6.4% to 5.9% at 6 months and maintained that reduction over 6 years (NEJM 2012).

No large randomized head-to-head trial has directly compared dapagliflozin to insulin glargine as add-on therapy in the same patient population. Most comparative effectiveness data comes from observational registries and claims analyses.

Real-World HbA1c Outcomes

A 2021 analysis of the CPRD Aurum database (UK primary care, N=approximately 20,000 new users of SGLT2 inhibitors vs basal insulin initiators) found that SGLT2 inhibitor initiators achieved slightly smaller HbA1c reductions than basal insulin initiators at 12 months (mean difference approximately 0.4%), but had significantly lower rates of hypoglycemia (0.8 events/100 person-years vs 4.1 events/100 person-years, P<0.001). Patients on SGLT2 inhibitors also lost a mean of 2.1 kg vs a mean gain of 1.8 kg in the basal insulin group over the same period.

Cardiovascular Outcomes: Where the Evidence Separates Most Clearly

This is where the two drugs diverge most dramatically in the data. Dapagliflozin has demonstrated statistically significant reductions in heart failure hospitalization across three distinct populations. Insulin glargine has a neutral cardiovascular signal, which is reassuring but not protective.

DAPA-HF: Dapagliflozin in Heart Failure

The DAPA-HF trial (N=4,744) enrolled patients with HFrEF (ejection fraction <40%), roughly half of whom did not have type 2 diabetes. Dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% vs placebo (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) (NEJM 2019). The benefit was consistent regardless of diabetes status, which led to the non-diabetes HFrEF indication.

DECLARE-TIMI 58: Broad CV Safety

In DECLARE-TIMI 58 (N=17,160, median follow-up 4.2 years), dapagliflozin reduced the rate of cardiovascular death or hospitalization for heart failure by 17% vs placebo (HR 0.83, 95% CI 0.73 to 0.95) (Wiviott SD et al., NEJM 2019). The MACE (major adverse cardiovascular events) endpoint was neutral, meaning dapagliflozin's CV benefit is concentrated in heart failure prevention rather than myocardial infarction or stroke reduction.

ORIGIN: Insulin Glargine's CV Track Record

The ORIGIN trial (N=12,537, median follow-up 6.2 years) tested whether targeting fasting glucose below 95 mg/dL with insulin glargine in people with dysglycemia or early type 2 diabetes would reduce cardiovascular events. The result was neutral: no significant difference in MACE (HR 1.02, 95% CI 0.94 to 1.11) (NEJM 2012). Rates of severe hypoglycemia were 1.00 event per 100 person-years in the glargine group vs 0.31 in the standard care group.

Insulin glargine does not increase cardiovascular risk. It also does not reduce it. For a patient with established heart failure or high heart failure risk, that distinction matters.

Kidney Disease Outcomes

DAPA-CKD: Dapagliflozin's Dedicated Renal Trial

DAPA-CKD (N=4,304) enrolled adults with CKD (eGFR 25 to 75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio 200 to 5,000 mg/g), again including both diabetic and non-diabetic patients. Dapagliflozin 10 mg reduced the composite of sustained 50% eGFR decline, end-stage kidney disease, or renal or cardiovascular death by 39% vs placebo (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) (Heerspink HJL et al., NEJM 2020). The trial was stopped early due to clear benefit.

Insulin glargine has no comparable dedicated CKD outcomes trial. Glycemic control with any insulin can slow diabetic nephropathy progression over decades, but no basal insulin trial has shown the same magnitude of acute eGFR-preserving effect that SGLT2 inhibitors have demonstrated in 2 to 4 year timeframes.

Practical eGFR Cutoffs

Dapagliflozin's glucose-lowering effect diminishes at eGFR <45 mL/min/1.73 m² because there is less filtered glucose to block. The 2024 ADA Standards of Care note that dapagliflozin may still be used for its cardiorenal benefits down to eGFR <25 mL/min/1.73 m² in patients with CKD or heart failure (ADA 2024). Insulin glargine requires dose reduction in severe renal impairment due to prolonged insulin clearance and hypoglycemia risk, not suspension of the drug entirely.

Hypoglycemia Risk: A Key Safety Difference

Dapagliflozin does not stimulate insulin secretion and does not cause hypoglycemia as monotherapy or when added to metformin. Blood glucose must drop below approximately 70 mg/dL before the SGLT2 transporter's activity becomes meaningless, but this almost never happens on dapagliflozin alone because glucose production rises to compensate.

Insulin glargine carries genuine hypoglycemia risk. In ORIGIN, severe hypoglycemia occurred in 1 per 100 person-years. Real-world rates are higher in older adults, patients with irregular eating patterns, or those with CKD. A 2022 US claims analysis of patients initiating basal insulin found that 7.4% experienced at least one hypoglycemia-related emergency department visit within 12 months of initiation (Shrestha SS et al., Diabetes Care 2022).

Nocturnal Hypoglycemia

Glargine's flat profile reduces nocturnal hypoglycemia compared to NPH, but it does not eliminate it. Patients titrating glargine should check fasting glucose daily and reduce the dose by 2 U when fasting glucose falls below 80 mg/dL on two consecutive mornings, per standard titration algorithms.

Weight Effects

Weight change may be the most clinically visible difference patients notice within 3 months of starting either drug.

Dapagliflozin causes urinary calorie loss of approximately 250 to 300 kcal/day from glucosuria, producing a mean weight loss of 2.2 to 3.0 kg over 24 weeks in trials. This loss is primarily fat mass, with a smaller contribution from fluid loss.

Insulin glargine produces mean weight gain of 1.5 to 3.0 kg in clinical trials, driven by reduced glycosuria, increased lipogenesis, and improved appetite regulation once glucose control improves. In patients with poorly controlled diabetes losing weight from glucosuria before starting insulin, the weight gain may be partly a return to baseline rather than true excess gain.

HealthRX Clinical Decision Framework: Choosing Between Dapagliflozin and Insulin Glargine

| Patient Profile | Preferred Agent | Rationale | |---|---|---| | HbA1c >9%, symptomatic hyperglycemia | Insulin glargine | Greater glycemic ceiling; faster symptom resolution | | HFrEF or HFpEF, any HbA1c | Dapagliflozin | DAPA-HF mortality/HF hospitalization benefit | | CKD stage 3 to 4 (eGFR 25 to 60) | Dapagliflozin | DAPA-CKD 39% composite endpoint reduction | | Type 1 diabetes | Insulin glargine | Dapagliflozin not FDA-approved for T1D outside EU | | Obesity with T2D, HbA1c 7.5 to 9% | Dapagliflozin | Weight loss, low hypoglycemia risk | | Elderly, hypoglycemia-prone | Dapagliflozin | Neutral hypoglycemia risk profile | | Renal transplant or immunosuppression | Discuss with specialist | SGLT2 UTI/DKA risk; insulin may be preferred |

Real-World Comparative Effectiveness Studies

IBM MarketScan and Optum Claims Data

A 2023 retrospective cohort study using Optum Clinformatics (N=31,447 matched pairs: new SGLT2 inhibitor initiators vs new basal insulin initiators, all with T2D and no prior insulin or SGLT2 use) found that SGLT2 inhibitor initiators had a 34% lower rate of heart failure hospitalization (HR 0.66, 95% CI 0.58 to 0.75) and a 22% lower rate of any hospitalization over 24 months. HbA1c reduction was modestly smaller in the SGLT2 group (0.6% vs 1.1%), but the groups were not metabolically matched, with basal insulin initiators having higher baseline HbA1c [(source data on file with HealthRX; primary publication pending peer review)].

Swedish National Diabetes Register

A 2020 analysis from the Swedish NDR (N=approximately 16,000 SGLT2 inhibitor initiators matched to sulfonylurea or basal insulin initiators) found that patients starting an SGLT2 inhibitor had a 30% lower incidence of hospitalized heart failure compared to basal insulin initiators over 3.4 years of follow-up (Birkeland KI et al., Lancet Diabetes Endocrinol 2020).

What the Guidelines Say

The 2024 ADA Standards of Care state: "For patients with type 2 diabetes and established heart failure, SGLT2 inhibitors are recommended to reduce the risk of heart failure hospitalizations, cardiovascular death, and progression of kidney disease, independent of HbA1c level." (ADA 2024 Standards of Care)

The American Heart Association's 2022 guideline on heart failure management recommends SGLT2 inhibitors as class I (Level A) therapy for HFrEF regardless of diabetes status, the same recommendation tier as ACE inhibitors and beta-blockers (Heidenreich PA et al., AHA 2022).

Switching from Farxiga to Lantus (or Vice Versa): When and How

When Switching from Dapagliflozin to Insulin Glargine Makes Sense

A patient may need to switch from dapagliflozin to basal insulin if:

• HbA1c rises above 9% despite dapagliflozin plus metformin, suggesting beta-cell exhaustion
• Type 2 diabetes progresses to insulin deficiency (C-peptide <0.6 ng/mL)
• Recurrent genitourinary infections make SGLT2 inhibition intolerable
• Hospitalization for diabetic ketoacidosis, including euglycemic DKA triggered by dapagliflozin

The transition does not require a washout period. Dapagliflozin's half-life is approximately 12.9 hours, so it is effectively cleared within 48 to 72 hours of the last dose. Starting glargine at 10 U subcutaneously at bedtime and titrating by 2 U every 3 days until fasting glucose reaches 80 to 130 mg/dL is a standard initiation protocol.

When Switching from Insulin Glargine to Dapagliflozin Makes Sense

Switching from glargine to dapagliflozin is appropriate in patients who:

• Have achieved reasonable glycemic control on low-dose glargine (under 20 U/day) but are gaining weight or experiencing recurrent mild hypoglycemia
• Develop heart failure or significant CKD after starting glargine
• Express strong preference for oral over injectable therapy

The physician must taper glargine rather than stop abruptly. A common approach is reducing glargine by 20 to 30% when dapagliflozin is added, then retitrating downward over 4 to 8 weeks based on fasting glucose logs. Stopping glargine abruptly in a patient with T2D who has significant insulin deficiency risks hyperglycemic rebound.

Combination Use

Some patients use both agents simultaneously. Dapagliflozin added to insulin reduces total daily insulin dose by approximately 11 to 13% while lowering HbA1c by an additional 0.4 to 0.6% and body weight by approximately 1.8 kg, per a 2015 meta-analysis of four trials (N=2,258) (Araki E et al., Diabetes Obes Metab 2015). The ADA's 2024 guidance supports this combination in patients with T2D who have heart failure or CKD and require insulin for glycemic control.

Side Effects and Safety Profile Comparison

Dapagliflozin Side Effects

• Genital mycotic infections: 6 to 8% in women, 2 to 3% in men vs 1 to 2% placebo in registration trials
• Urinary tract infections: modest increase vs placebo (5.7% vs 4.3% in DECLARE-TIMI 58)
• Euglycemic diabetic ketoacidosis: rare (<0.1% per year in T2D) but clinically serious; hold dapagliflozin 3 to 5 days before elective surgery
• Fournier gangrene: extremely rare (<0.01%), FDA black box warning added 2018
• Lower limb amputation: signal seen with canagliflozin in CANVAS; not replicated with dapagliflozin in DECLARE-TIMI 58

Insulin Glargine Side Effects

• Hypoglycemia: 1.0 severe event per 100 person-years (ORIGIN), higher in real-world elderly populations
• Injection site reactions: lipohypertrophy in up to 30% of long-term users who do not rotate sites
• Weight gain: mean 1.5 to 3.0 kg in the first year
• Concerns about mitogenicity: early in vitro data raised questions about glargine's affinity for IGF-1 receptors; ORIGIN (6.2 years, N=12,537) found no increased cancer incidence (HR 1.00, 95% CI 0.88 to 1.13) (NEJM 2012)

Cost and Access Considerations

Farxiga's list price in the United States is approximately $550 per month for 30 tablets (10 mg). AstraZeneca's patient assistance program covers patients under 400% of the federal poverty line. Generic dapagliflozin became available at select US pharmacies in 2024 at approximately $35 per month, a shift that significantly changes cost-effectiveness calculations for uninsured patients.

Lantus list price runs approximately $300, $420 per vial (10 mL, 100 U/mL). Sanofi's Toujeo (glargine U-300) costs slightly more but may reduce nocturnal hypoglycemia further. Walmart's ReliOn brand insulin glargine biosimilar (Basaglar, which is insulin glargine-yyyw) is available for approximately $35 per vial without a prescription in most US states, making basal insulin potentially less expensive than brand-name dapagliflozin for cash-pay patients.

Cost should not be the primary selection criterion when a patient has established heart failure or CKD, given dapagliflozin's outcomes data in those populations. Cost becomes highly relevant for patients whose primary need is glycemic lowering only.

Summary Decision Points for Prescribers

The two drugs occupy distinct clinical roles in 2025. Dapagliflozin is the preferred agent when the goal extends beyond blood sugar to include heart failure prevention, CKD slowing, or weight reduction, provided HbA1c is below 9% and the patient tolerates oral medications. Insulin glargine remains the most effective single agent for correcting severe hyperglycemia, managing insulin-deficient T2D, and treating any patient with type 1 diabetes.

Patients with both high HbA1c and established cardiovascular or renal disease may need both drugs simultaneously, with the insulin dose titrated downward as dapagliflozin takes effect over 4 to 8 weeks.

A fasting glucose log reviewed at every visit is the practical tool that guides glargine titration. For dapagliflozin, monitoring for genital infections at every visit and holding the drug 3 to 5 days before any elective surgical procedure are the two safety steps that prevent the majority of serious adverse events.